The restrictions adopted during the coronavirus disease 2019 (COVID-19) pandemic limiting direct medical consultations and access to healthcare centers reduced the participation of patients with chronic diseases, such as osteoporosis (OP), in screening and monitoring programs. This highlighted the need for new screening diagnostic tools that are clinically effective, but require minimal technical and time commitments, to stratify populations and identify who is more at risk for OP and related complications. This paper provides an overview of the potential use of blood-related factors, such as platelet (PLT)- and monocyte-related factors, as biomarkers able to quickly screen, detect, and monitor OP in both sexes. Such biomarkers might be of key importance not only during the COVID-19 pandemic but also, even more importantly, during periods of better global health stability.

2019 年冠状病毒病 (COVID-19) 大流行期间采取的限制直接医疗咨询和进入医疗中心的限制减少了骨质疏松症 (OP) 等慢性病患者对筛查和监测计划的参与。这突出表明需要新的临床有效的筛查诊断工具，但需要最少的技术和时间承诺，以对人群进行分层并确定谁更容易患 OP 和相关并发症。本文概述了血液相关因子（例如血小板 (PLT) 和单核细胞相关因子）作为能够快速筛查、检测和监测两性 OP 的生物标志物的潜在用途。这些生物标志物可能不仅在 COVID-19 大流行期间至关重要，而且更重要的是，